MERRIMACK, New Hampshire, October 1 /PRNewswire/ --

DxTech LLC ("DxTech"), an innovative company focused on defining a new direction in global diagnostics by putting high-quality diagnostic information in the hands of the physicians in real time, has received development funding from PetroTech Holdings Corp., a majority owned subsidiary of the Laurus Family of Funds.

DxTech is developing the fully-integrated Vantix(TM) point-of-care ("POC") diagnostics system based on proprietary P3 Technology(TM) electrochemical sensor technology that has unparalleled sensitivity and dynamic range. The Vantix system is designed to unlock the potential of POC testing by matching the performance levels established by US reference laboratories, being CLIA ("Clinical Laboratory Improvement Amendments") waivable, improving patient care and practice economics, and thereby meet the global need for distributed diagnostics. In the US market, demand for the Vantix system is expected to result from providing the physician with reference lab quality results, increased practice efficiency and additional revenue to the physician.

According to Steve Lufkin, CEO of DxTech, "This funding provides us the resources to further develop the ability of the P3 Technology biosensor to deliver a unique level of assay sensitivity and broad dynamic range."

To learn more about DxTech please visit www.dxtech.com.

Web site: http://www.dxtech.com

Steve Lufkin of DxTech LLC, +1-603-882-9060, Fax: +1-603-882-2582